Sanofi, a French multinational pharmaceutical company, completed the acquisition of Synthorx, a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, for $2.5bn. The $68 per share acquisition price represented a 172% premium to Synthorx’s closing price on December 6, 2019. "The acquisition of Synthorx perfectly aligns with our R&D strategy, enhancing our position as an emerging leader in the area of oncology and immunology. We gain access to both great scientists and science with THOR-707, an engineered not-alpha IL-2 for the treatment of solid tumors which induces strong immunological responses in vivo, additional intriguing pre-clinical assets, and a powerful platform that complements our ongoing oncology and immunology research," Paul Hudson, Sanofi Chief Executive Officer.